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Abstract Tryptase TL, purified from MOLT-4 human T cells 
binds to the envelope protein of human immunodeficiency virus 
type 1 (HIV-l). Tryptase TL, and CD26 antigen are supposed 
to play roles in HIV-l entry into cells. Although CD4 is a princi- 
pal receptor for HIV-l, brain cells expressing the CD4 antigen 
are not permissive to HIV-l strains infectious to monocyte or 
T-cell lines. We examined whether the non-permissiveness of the 
brain-derived cells to standard HIV-l strains could be explained 
by a lack of tryptase TL, or CD26. Western blots showed that 
the amounts of tryptase TLa expressed in cell lysates prepared 
from the brain-derived cells were similar to those prepared from 
various cells susceptible to HIV-l strains. Furthermore, flow 
cytometry revealed the presence of the CD26 antigen on the cell 
surface of many types of cells. The resistance of the brain-derived 
ceils to standard HIV-l strains is not due to a lack of tryptase 
TL, or CD26. 
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1. Introduction 
Human immunodeficiency virus type 1 (HIV-l) is the causa- 
tive agent of AIDS [l-3]. Numerous HIV-l strains have been 
isolated by co-cultivation of peripheral blood lymphocytes 
(PBL) of HIV-l positive subjects with PHA-stimulated PBL or 
human T-cell lines [24]. HIV-l strains infectious to human 
T-cell lines such as MOLT-4, MT-4, MT-2, CEM, H9 or 
C8 166, or monocytic cell lines such as U937, have been prefer- 
entially isolated from patients who show clinical signs of AIDS 
or AIDS-related complex [3-61. These isolates, however, will 
not enter cells derived from the human brain or skin, even 
though these cells are made to express the CD4 antigen [7,8]. 
It has also been reported that mouse cells expressing the human 
CD4 antigen are not infectable with standard HIV-l strains [9]. 
These lines of evidence suggested that the presence of the CD4 
antigen is not sufficient to support HIV-l entry into cells. 
Tryptase TL, has been reported to bind to the gpl20 enve- 
lope protein and it is supposed to play a role in HIV-l entry 
into cells [lO,l 11. This enzyme is a serine protease expressed on 
the cell surface of the MOLT-4 human T-cell line. The antise- 
rum against it inhibits syncytium formation induced by the 
co-cultivation of MOLT-4 cells with HIV-l producing cells. We 
suggested that the binding of the V3 loop of gpl20 to tryptase 
TL, is necessary for infection with HIV-l [1 I]. This enzyme 
recognizes the glycine-prolineeglycine-arginine (GPGR) 
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sequence, which is also located at the tip of the V3 loop of most 
standard HIV-l strains. 
We reported the isolation of HIV-l variants infectious to 
CD4-positive brain cells from a T-cell line-tropic, wild-type 
virus [ 121. This variant has a glycine-serine-glycine-arginine 
(GSGR) sequence at the top of the V3 loop. The wild-type 
viruses which have the GPGR sequence in the V3 loop readily 
infect T-cell line cells, but hardly infect brain-derived cells even 
though they express CD4. Thus, brain-derived cells may lack 
tryptase TL,. We examined whether tryptase TL, is present in 
brain-derived cells and T cells by Western immunoblotting. 
Recently, the CD26 antigen has been reported as a possible 
cofactor in HIV-l infection and it may be responsible for deter- 
mining the cell tropism of HIV- 1 [ 131. There seems to be contro- 
versy among reports concerning the role of CD26 in HIV-l 
infection [1418]. We also examined its expression in brain- 
derived cells. 
2. Materials and methods 
2.1. Ceils and viruses 
The human T-cell lines MT-4 [19], MOLT-4 [20] and C8166 [21] were 
maintained in RPM11640 medium supplemented with 10% (v/v) fetal 
calf serum (FCS). Human glioma cell lines U-87 MG [22], U-251 MC 
[23], NP-1 and NP-2 [24], and U-87KD4 stably expressing the human 
CD4 gene [7] were maintained in Eagle’s minimum essential medium 
(EMEM) supplemented with 10% FCS. The human cervical carcinoma 
cell line HeLa [25], the CD4-expressing subline HeLaKD4 [26] and the 
human osteosarcoma cell line HOS [27] were also maintained in EMEM 
with 10% FCS. The human fibroblast-like cell strains BT-2 and BT-3 
derived from surgically dissected human astrocytoma and meningioma, 
respectively, were cultured as described [12]. The expression of CD4 
mRNA and CD4 antigen in BT-2 and BT-3 cells was confirmed by 
Northern blotting and immunoprecipitation (unpublished data). 
Human peripheral blood lymphocytes (PBL) were isolated by Ficoll- 
Paque (Pharmacia, Uppsala) gradient centrifugation. stimulated with 
PHA-P (1: 1000) for 2 days, then cultured in RPM11640 medium con- 
taining 10% FCS and 200 units/ml recombinant interleukin 2. 
The HIV-l strains GUN-l/WT and GUN-l/V were isolated as de- 
scribed elsewhere [12,28]. Briefly, GUN-l was isolated from a Japanese 
hemophiliac by co-cultivating his PBL with MT-4 cells. The GUN-l/ 
WT substrain 5M was obtained by transfecting infectious GUN-l/ rWT 
DNA into MT-4 cells. The GUN-l/V substrain r9V was isolated by 
adaotinu GUN-l/rWT virus (5M) to U-87KD4 cells. Culture fluids of 
MdLT-i cells persistently infected with GUN-I/WT and HTLV-III, 
strains [4] and U-87/CD4 cells infected with GUN-l/V were used as the 
sources of HIV-I strains. 
2.2. Virus infection 
Adherent cells were seeded into 12 well-plates at a density of 335 x lo4 
cells in 2 ml of culture medium. On the following day, the medium was 
removed and serially diluted viruses were inoculated onto them. The 
lowest dilutions of inocula were adjusted so as to contain 4.0 x IO5 cpm 
of reverse transcriptase (RT) activity. 2 h later, the inocula were re- 
moved, then the cells were passaged every 5-6 days. Non-adherent 
MOLT-4, C8166 or MT-4 cells (1 x 105) were incubated with viruses for 
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2 h, washed once and cultured for 4 days. The percentages of cells 
expressing HIV-l antigens were determined by indirect immunofluores- 
cence assay (IFA) as described elsewhere [29]. 
2.3. Western blot 
Western blotting proceeded as described previously [lo]. Briefly, cells 
were suspended in lysis buffer consisting of 50 mM Tris-HCl (pH 6.5), 
0.2% 3-[(3-chloamidopropyl)-dimethylammonio]-l-propanesulfonate 
(CHAPS). 0.5 M NaCl, 50 PM L-trans-epoxysuccinyl-leucylamido-(4- 
guanidinobutane) (E-64), 50pM chymostatin, 50pM leupeptin, 50pM 
1, IO-phenanthroline and 50 PM bestatin and homogenized. After cen- 
trifugation of the cell lysates at 25,000 x g for 20 min, the supernatants 
were used as samples. The cell lysates containing 5 pug protein were 
resolved by lo-20% polyacrylamide gradient gel electrophoresis in the 
presence of sodium dodecyl sulfate (SDS-PAGE) and transferred to 
nitrocellulose membranes. These were incubated with polyclonal anti- 
tryptase TL2 rabbit antiserum and examined using the pica Blue Kit 
(Stratagene, La Jolla. CA) according to the manufacturer’s instruc- 
tions. Bands detected were scanned with a densitometer (Atto, 
Tokyo). 
2.4. Flow cytometry of the CD26 and CD4 antigens on the cell surfuce 
Adherent cells were incubated with phosphate-buffered saline (PBS) 
containing 0.5 mM EDTA for 10 min at 37”C, then mechanically 
detached using a cell scraper. Cell suspensions (1 x 10’ cells/ml) were 
incubated with the Tal anti-CD26 (Coulter Immunology, Hialeah, FL) 
or Leu3a (Becton Dickinson, San Jose, CA) or NU TH/I (Nichirei, 
Tokyo. Japan) anti-CD4 monoclonal antibodies at 0°C for 20 min. 
Then cells were incubated with fluorescent isocyanate-conjugated rab- 
bit anti-mouse IgG as the second antibody at 0°C for 20 min, then fixed 
with 1% paraformaldehyde. In some experiments, cells were first 
treated with 10% normal rabbit serum in PBS to block Fc receptors on 
the cell surface and processed as described above. The expression of the 
CD26 or CD4 antigens on the surface of various cells was examined 
using a flow cytometer (CytoACE 150; JASCO Co., Tokyo). The ratios 
of antigen-positive cells were determined as described below. Cells 
stained with the second antibody alone provided the negative control. 
The cut-off level of fluorescence intensity of each cell line, by which 95 
and 5% of the control cells were classified as being stained negative and 
positive, respectively, was determined as shown by the arrows in Fig. 
3. Ratios of antigen-positive cells (%) were determined after incubating 
cells with the first and second antibodies as follows: percentage of 
antigen-positive cells = percentage of cells with a fluorescence intensity 
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3. Results 
3.1. Susceptibility of human cells to HIV-I 
We compared the susceptibility of human T cells and brain- 
derived cells to HIV-l. The human T-cell lines C8166, MT-4 
and MOLT-4 were infected with three HIV-I strains and exam- 
ined by IFA after cultivation for 4 days. MT-4 and C8166 cells 
were readily infected with the HTLV-III,, GUN-l/WT or 
GUN-l/V strains of HIV-l (Fig. IA and data not shown). 
Although a low ratio of MOLT-4 cells were positive for HIV-I 
antigens after infections with the three viruses (Fig. 1 B), almost 
all cells became positive for HIV-l antigens after several pas- 
sages (data not shown). HeLaKD4 cells were also susceptible 
to THLV-III, (Fig. 1C) and most cells became infected after 
a few cell passages (data not shown). GUN-l/WT plated much 
less efficiently onto HeLa/CD4 cells than HTLV-III, (Fig. I C): 
most cells still became positive for HIV-I antigens after several 
passages. In contrast, GUN-IIWT or HTLV-III, could not 
plate onto brain-derived BT-2, BT-3 or U-871CD4 cells (Fig. 
ID-F). Even after several cell passages, these cells remained 
negative for HIV-l antigens ( < 1%). That is, human T cells or 
HeLalCD4 cells were infectable with both types of HIV-I 
strains and permitted further spread of HIV-l to uninfected 
cells. In contrast, CD4-positive, brain-derived cells were almost 
completely resistant to standard T-cell line-tropic strains, and 
the secondary spread of HIV-l in them was not detected even 
after many cell passages. The GUN-l/V strain plated efficiently 
onto these brain-derived cells (Fig. I D-F). All cell lines which 
did not express CD4 antigen, such as U-87 MG, U-251 MG, 
NP-1, NP-2, HeLa and HOS cells (Table 1). were not suscepti- 
ble to the three HIV-1 strains. Thus the CD4 antigen was 
necessary for the infection of these cells with HIV-I. 
3.2. Western blots of tryptuse TL, 
Brain-derived cells were resistant to infection with standard 
HIV-l strains as reported [7,8]. We examined whether tryptase 
- B 
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Fig. 1. The susceptibility of human cells to three HIV-I strains. Cells were infected with HIV-1 and the expression of HIV-I antigens was detected 
by IFA. (A) MT-4; (B) MOLT-4; (C) HeLa/CD4; (D) BT-2; (E) BT-3: (F) U-87/CD4. 
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Fig. 2. Western blots of tryptase TL, in various human cells. Cell lysates were resolved by SDS. Lanes: 1, MOLT-4; 2, U-251 MG; 3, NP-I; 4, NP-2; 
5, U-87 MG; 6, U-87/CD4; 7, BT-2; 8, BT-3; 9, HOS; 10, HeLa; 11, HeLalCD4. 
TL, was present in brain-derived cells as well as human T cells. 
A polyclonal antibody against tryptase TL, was used for West- 
ern blotting. In all the cells examined, we detected two bands 
corresponding to apparent molecular masses of 32 and 28 kDa 
(Fig. 2), which were considered to be the two main subunits of 
tryptase TL,, as reported [lo], although amounts of tryptase 
TL, expressed on the cell surface were unknown. The bands 
form MOLT-4 cells were the most prominent, and the relative 
intensities of other bands were determined by densitometry 
(Table 1). The BT-2 cell lysate gave the faintest bands and the 
relative intensities of the two bands of the other cells were 
within 20-57% of those of MOLT-4 cells. Although the 
amounts of tryptase TL, expressed in U-87/CD4, MT-4 and 
HeLaKD4 cells were similar, there was a marked difference in 
their susceptibility to standard HIV-l strains. 
lated PBL expressed CD26 antigen (Fig. 3 and Table 1). Half 
of the MOLT-4 cells and about 20% of U-871CD4, U-87 MG 
and HOS cells were judged to be positive for this antigen (Fig. 3 
and Table 1). As for other cell lines such as C8166 or MT-4 
cells, less than 10% of the cells were positive for the CD26 
antigen on their cell surface. Brain-derived cells may express Fc 
receptors on their surface. However, about half of U-87 MG 
and U-87/CD4 cells were again positive for CD26 even when 
these cells had been treated with 10% normal rabbit serum 
before anti- CD26 monoclonal antibody in order to block Fc 
receptors (data not shown). The CD26 antigen was expressed 
on the cell surface of not only T cells, but also of brain-derived 
cells such as U-87/CD4 and U-87 MG. 
3.3. Flow cytometry of CD26 and CD4 antigen 
The CD26 antigen was another potential cofactor of HIV-l 
infection [13]. The expression of the CD26 or CD4 antigens on 
the cell surface was examined by flow cytometry. When PBL 
were reacted with anti-CD4 monoclonal antibody, two peaks 
appeared (Fig. 3A). When other cells were examined, single 
peaks of fluorescence intensity shifted to the right if cells were 
positive for CD26 or CD4 antigen. About 90% of PHA-stimu- 
Expression of CD4 antigen was examined to evaluate our 
assay conditions. All T-cell lines such as MOLT-4, C8 166 or 
MT-4 and U-87KD4 and HeLaJCD4 cells expressed CD4 anti- 
gen (Fig. 3 and Table 1) as reported [7,26,29,30]. About 15% 
of the BT-2 cells were positive for this antigen. Less than 3% 
of cells expressed CD4 antigen in other lines, and these cells 
were considered to be negative for CD4 antigen. Pretreatment 
of U-87 MG or U-871CD4 cells with normal rabbit serum again 
did not essentially affect their ratios of CD4-positive cells (data 
not shown). The results for the CD4 antigen were consistent 
with those of previous reports. 
Table 1 
Detection of tryptase TL, and CD26 and CD4 antigens in various human cells 
Cell Tryptase TL, (%) 
Designation Origin 32 kDa 28 kDa 
















T cell leukemia 
T cell of cord blood 










100” 59 4gb 
ND ND 10 
ND ND 8 
54 21 4 
25 9.3 3 
44 17 5 
53 13 68 
49 20 53 
2.2 < 0.1 10 
32 18 NAd 
57 12 19 
49 27 8 
47 17 5 















a Relative intensities of bands determined by densitometry. The intensity of the 32 kDa band of MOLT-4 cells was taken as 100%. 
bAntigen positive cells (%) were determined as described in section 2. 
’ ND, not done. 
‘NA, not applicable due to cell damage. 
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Fig. 3. Flow cytometry of the CD26 antigen on the cell surface. PBL (A), MOLT-4 (B) and U-87KD4 (C) cells were reacted with Tal anti-CD26 
monoclonal antibodv and examined bv flow cvtometrv. Arrows indicate the cut-off levels of the fluorescence intensity of the control cells which were 
reacted with the FITC-conjugated second a&body alone. 
4. Discussion 
During infection with paramyxovirus, such as Sendai virus 
or Newcastle disease virus, or retrovirus, such as HIV-l, viruses 
enter cells by means of membrane fusion, which occurs at the 
cell surface [31-331. Other enveloped viruses, such as influenza 
virus, enter cells by endocytosis [34]. Cellular protease is 
thought to be necessary for the membrane fusion process: the 
fusion activity of envelope proteins will appear upon their pro- 
teolytic cleavage by host cell proteases [32,35,36]. Furthermore, 
the cell tropism of paramyxoviruses is reportedly determined 
by these proteases, while receptors for them are ubiquitously 
present on the cell surface [31,32]. The CD4 antigen serves as 
the main receptor for HIV-l, but an additional factor is sup- 
posed to be required for the entry of HIV-l into cells. It is 
probable that the presence or absence of this factor is closely 
related with the cell tropism of HIV- 1. Namely, the cell tropism 
of HIV-l may be determined by a factor other than the CD4 
antigen, one of which may be a cellular protease. If cells lack 
this factor or the substrate specificity of a putative protease in 
the cells is different from T cells, they may not be susceptible 
to standard HIV-l strains. 
Tryptase TL2 is a serine protease that is located on the sur- 
face of the MOLT-4 human T-cell line. Its protease activity is 
markedly inhibited by compounds containing the glycine-pro- 
line-glycine-arginine (GPGR) or GPCR sequences such as 
Kuniz-type serine protease inhibitors, gp120 of HIV-l or the 
oligopeptides derived from the V3 loop of gp120; furthermore, 
the GPGR sequence in the V3 loop is recognized by tryptase 
TL, [lo]. 
T-cell line-tropic HIV-l strains such as HTLV-III, and 
GUN-l/WT that have the GPGR sequences at the tip of the 
V3 loop of gp120 plate well onto T-cell lines but not onto 
brain-derived, CD4-positive cells. We showed that a single 
point mutation at proline of the GPGR sequence in the V3 
region is responsible for this brain cell tropism [12]. We further 
isolated new variants infectious to the brain-derived cells and 
they had a GSGR, GAGR or GTGR sequence at the tip of the 
V3 loop [37]. These findings suggested that brain cells may not 
recognize the GPGR sequence. In this report we confirmed that 
brain-derived cells were almost totally resistant to infection 
with T-cell line-tropic HIV-l strains (Fig. 1) that have the 
GPGR sequence in the V3 loop. 
Therefore, we examined whether the brain cells lack tryptase 
TL,. Western blots showed that most cells expressed this pro- 
tease whether they were derived from T cells, brain cells or 
other human tissues (Fig. 2). Tryptase TL, in MOLT-4 cells has 
recently been identified to be composed of at least three isomers 
with similar molecular masses and is localized not only in the 
cell membrane but also in the cytosol (Kido et al., in preparation). 
These data suggest that isoforms of tryptase TL, on the cell 
surface of brain-derived cells are different from those in T cell 
membranes, or that brain-derived cells may contain another 
protease which immunologically cross-reacts with anti-tryp- 
tase TL, antiserum but hardly reacts with the GPGR se- 
quence. Furthermore, it remains to be investigated whether 
tryptase TL, isomers on the surface of T cells or brain-derived 
cells will recognize the GSGR, GAGR or GTGR sequence as well 
as the GPGR sequence. If the tryptase TL, isomers in brain- 
derived cells recognize the GPGR sequence, we should suppose 
that another factor determines the cell tropism of HIV-l. 
The CD26 antigen has been implicated as a cofactor in the 
infection of T cells with HIV-l [13]. This antigen has been 
described as dipeptidylpeptidase IV, which may recognize 
amino-terminal dipeptide motifs such as the GP, KP or RP 
sequence present in the V3 loop after endoproteolytic cleavage, 
and is abundantly expressed on the surface of activated T cells 
[ 13,38,39]. The possibility that brain cells lack this antigen was 
examined by flow cytometry (Fig. 3 and Table 1). These analy- 
ses showed that the human glioma cell lines, U-87 MG or 
U-87KD4 expressed the CD26 antigen, as does the human T 
cell line, MOLT-4. 
Tryptase TL, or CD26 antigen are thought to be cellular 
factors which are required for the entry of HIV-l into cells and 
may also determine the cell tropism of HIV-l strains. Here, we 
showed that the resistance of CD4-positive brain cells to stand- 
ard HIV-l strains could not be explained by a lack of tryptase 
TL, in the cells or CD26 antigen on the cell surface. It remains 
to be determined which factor is necessary for the entry of 
HIV-l into cells in addition to the CD4 antigen. 
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